CAU
TERN

Caxton Associates (UK)’s Terns Pharmaceuticals TERN Stock Holding History

Caxton Associates (UK)’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.99M Buy
+94,724
New +$3.89M 0.11% 64
2025
Q4 		– Sell
-15,168
Closed -$114K – 968
2025
Q3 		$114K Buy
+15,168
New +$96.9K ﹤0.01% 666

Other funds holding TERN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Caxton Associates (UK)'s TERN Position: Q1 2026 in Review

Caxton Associates (UK) opened a new position in Terns Pharmaceuticals (TERN) in Q1 2026: 94,724 shares worth $4.99M. The stake represents 0.11% of the portfolio and ranks #64 among its holdings. This is a return to the name: Caxton Associates (UK) previously reported a position in TERN as recently as Q3 2025.

Caxton Associates (UK) first reported a position in TERN in Q3 2025 and has held it in 2 quarters since. 317 funds tracked by Wall St. Rank hold TERN as of Q1 2026.

  • Caxton Associates (UK) held 94,724 shares of Terns Pharmaceuticals worth $4.99M as of Q1 2026.
  • Terns Pharmaceuticals was a new Caxton Associates (UK) position in Q1 2026.
  • Terns Pharmaceuticals made up 0.11% of Caxton Associates (UK)'s portfolio in Q1 2026, its #64 holding.
  • Caxton Associates (UK) first reported a position in Terns Pharmaceuticals in Q3 2025 and has held it in 2 quarters since.
  • 317 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q1 2026.

Based on Caxton Associates (UK)'s 13F filing for Q1 2026, filed 14 May 2026.